Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BSI 038

Next Previous
X
Search
Drug Profile

BSI 038

Alternative Names: Anti-CD40 monoclonal antibody - Biosion; BSI-038

Latest Information Update: 11 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biosion
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen stimulants; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 08 May 2023 Biosion has a licensing agreement with Chia Tai Tianqing Pharmaceutical Group to develop and commercialize BSI 038 for Solid tumours in China
  • 19 May 2022 BSI 038 is available for licensing as of 19 May 2022. https://www.biosion.com/pipeline/bsi-038/
  • 27 Apr 2022 Phase-I clinical trials in Solid tumours (In adults, In the elderly, Late-stage disease, Second-line therapy or greater) in China (IV, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top